This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| DiaSorin | |
|---|---|
| Name | DiaSorin S.p.A. |
| Type | Public |
| Founded | 1968 |
| Founder | Carlo Rosa |
| Headquarters | Saluggia, Province of Vercelli, Italy |
| Area served | Worldwide |
| Industry | In Vitro Diagnostics |
| Products | Immunodiagnostics, Molecular Diagnostics, Point-of-Care tests |
| Revenue | €1.9 billion (2023) |
| Num employees | 5,000+ (2024) |
DiaSorin
DiaSorin is an international company specializing in in vitro diagnostics, headquartered in Saluggia, Province of Vercelli, Italy. It operates across Europe, the Americas, and the Asia-Pacific region, supplying immunoassay and molecular diagnostic systems to clinical laboratories, hospitals, and public health agencies. The company is known for assay platforms, reagents, and integrated diagnostic solutions used in infectious disease testing, oncology, endocrinology, and transplantation medicine.
Founded in 1968 by Carlo Rosa near Turin, the company expanded from regional reagent production into multinational diagnostics through organic growth and acquisitions. Key milestones include geographic expansion into France, Germany, and the United States, and strategic purchases of technology providers from biotechnology clusters in Boston and Milan. During the early 2000s, leadership shifts paralleled consolidation trends in the European Union diagnostics market and responses to directives such as the In Vitro Diagnostic Directive 98/79/EC. The company navigated market changes influenced by events including the 2008 financial crisis and the COVID-19 pandemic, during which demand for molecular assays and serology tests surged. Over decades, it has formed partnerships with research institutions like the University of Turin, collaborations with industry peers in Silicon Valley, and participation in international standards discussions at organizations such as the International Organization for Standardization.
Operations encompass research and development, manufacturing, sales, and distribution across regions including North America, South America, Europe, Asia, and Oceania. Manufacturing sites and logistics hubs are situated near industrial centers in Lombardy, Piedmont, and distribution branches in New Jersey and São Paulo. The company sells through direct commercial teams, distributors, and strategic alliances with hospital networks such as Mayo Clinic and procurement consortia like those linked to the National Health Service (England). Corporate strategy aligns with regulatory frameworks including the European Medicines Agency and the U.S. Food and Drug Administration, and procurement cycles influenced by institutions such as World Health Organization tenders.
Product lines include automated immunoassay platforms, molecular diagnostic systems, reagents, and consumables supporting assays for pathogens like SARS-CoV-2, HIV, and Hepatitis C virus as well as markers used in oncology and transplantation monitoring. Assay development employs technologies related to chemiluminescence, polymerase chain reaction, and next-generation sequencing workflows with integration into laboratory information systems used by facilities such as Cleveland Clinic and Johns Hopkins Hospital. Product support covers service contracts, calibration materials, and training programs delivered in conjunction with professional bodies such as the European Society of Clinical Microbiology and Infectious Diseases.
R&D centers collaborate with academic partners, biotech firms, and public health laboratories to advance diagnostics for emerging pathogens and chronic conditions. Programs have targeted assay sensitivity improvements, automation, and multiplexing capabilities through partnerships with research groups at Imperial College London, Karolinska Institutet, and the Pasteur Institute. Grant-funded research links to initiatives by the European Commission and consortia involving Horizon 2020 projects. Intellectual property portfolios include patents filed in jurisdictions like United States Patent and Trademark Office and the European Patent Office.
The company is publicly traded on the Borsa Italiana with a board of directors and executive management responsible for strategy, compliance, and stakeholder relations. Institutional investors such as asset management firms in London and New York City hold significant share blocks, while reporting obligations require adherence to listing rules enforced by CONSOB. Governance practices reference codes promoted by entities like the Italian Stock Exchange Group and interactions with proxy advisors including Institutional Shareholder Services.
Revenue streams derive from product sales, service contracts, and licensing; recent fiscal reports reflected revenues driven by demand for infectious disease testing and recurring consumables. Financial metrics influenced by currency exposure to the U.S. dollar and Brazilian real are monitored by treasury and investor relations teams. Capital allocation has included investments in manufacturing capacity, acquisitions in North America, and R&D spend benchmarked against peers listed on indices such as the FTSE MIB.
The company has faced regulatory scrutiny and litigation typical of the diagnostics industry, including disputes over patent infringement brought before courts in Milan and New Jersey, compliance inspections by notified bodies under the European Union regulatory framework, and contractual disagreements with distributors in markets such as Argentina. During the COVID-19 pandemic, pricing and supply allocation were subjects of public debate involving health authorities in Italy and procurement challenges in Spain. Corporate responses have involved settlements, corrective actions, and enhanced compliance measures coordinated with external counsel from firms in Paris and London.
Category:In vitro diagnostics companies Category:Companies of Italy